AURA - Company ID 0001501796
The table below shows Aura Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$84.74M | -$79.81M | -$63.85M | -$54.60M | -$32.41M | -$24.32M |
| Capital expenditure | $447.00K | $1.25M | $709.00K | $1.09M | $2.13M | $771.00K |
| Investing cash flow | $35.59M | $68.82M | -$113.96M | -$67.87M | -$2.13M | -$771.00K |
| Dividends paid | - | - | - | - |
Aura Biosciences, Inc. reported operating cash flow of -$84.74M for fiscal year 2025. That is down 6.2% from -$79.81M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$24.32M (FY 2020) to -$84.74M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $77.16M | $1.59M | $97.29M | $95.63M | $166.26M | $10.04M |